EFTA00847190.pdf

From: "Barrett, Paul S" To: "Jeffrey Epstein (sevaeation@gmall.eom)" <jeevaeation@gmail.eom> CC: Barrett Team Subject: To Do Date: Thu, 03 Sep 2015 12:48:02 +0000 Jeffrey I am still waiting on the Balance Sheet so we can get the ISDA done. KRW still weakening. Asia FX should continue to weaken. But LB should do $2MM in a SP500 Market Plus Note (17.5% buffer; unlimited upside) and $1MM in the Merck idea we had sent yesterday. You free to discuss? Paul Paul Barrett I Managing Director j Global Investment Opportunities Group j 3.P. Morgan Securities LLC I J.P. Morgan Private Bank I 3.P. Morgan Chase Bank N.A. 320 Park Avenue, 14th Floor, New York, NY 10022 I T: NOT AN OFFICIAL CONFIRMATION: For informational purposes only. This report does not represent an official account of the holdings, balances, or transactions made in your account and is being provided at your request. Please refer to your monthly account statement for the official record of all of your account activities. For question, please call your J.P. Morgan representative. In discussion of options and other strategies, results and risks are based solely on hypothetical examples cited; actual results and risks will vary depending on specific circumstances. Investors are urged to consider carefully whether option or option-related products in general, as well as the products or strategies discussed herein are suitable to their needs. In actual transactions, the client's counterparty for OTC derivatives applications is JPMorgan Chase Bank, N.A., and affiliates. For a copy of the "Characteristics and Risks of Standardized Options" booklet, please contact your JPMorgan Advisor. This email is confidential and subject to important disclaimers and conditions including on offers for the purchase or sale of securities, accuracy and completeness of information, viruses, confidentiality, legal privilege, and legal entity disclaimers, available at I tp://www.ipmorgan.com/pages/disclosures/email. This email is confidential and subject to important disclaimers and conditions including on offers for the purchase or sale of securities, accuracy and completeness of information, viruses, confidentiality, legal privilege, and legal entity disclaimers, available at http:f/www.jpmorgan.comlpagesldisclosures/email EFTA00847190